Cargando…
A comparison of Percutaneous femoral access in Endovascular Repair versus Open femoral access (PiERO): study protocol for a randomized controlled trial
BACKGROUND: Access for endovascular repair of abdominal aortic aneurysms (EVAR) is obtained through surgical cutdown or percutaneously. The only devices suitable for percutaneous closure of the 20 French arteriotomies of the common femoral artery (CFA) are the Prostar™ and Proglide™ devices (Abbott...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570236/ https://www.ncbi.nlm.nih.gov/pubmed/26370286 http://dx.doi.org/10.1186/s13063-015-0911-y |
_version_ | 1782390170410024960 |
---|---|
author | Vierhout, Bastiaan P. Saleem, Ben R. Ott, Alewijn van Dijl, Jan Maarten de Kempenaer, Ties D. van Andringa Pierie, Maurice E. N. Bottema, Jan T. Zeebregts, Clark J. |
author_facet | Vierhout, Bastiaan P. Saleem, Ben R. Ott, Alewijn van Dijl, Jan Maarten de Kempenaer, Ties D. van Andringa Pierie, Maurice E. N. Bottema, Jan T. Zeebregts, Clark J. |
author_sort | Vierhout, Bastiaan P. |
collection | PubMed |
description | BACKGROUND: Access for endovascular repair of abdominal aortic aneurysms (EVAR) is obtained through surgical cutdown or percutaneously. The only devices suitable for percutaneous closure of the 20 French arteriotomies of the common femoral artery (CFA) are the Prostar™ and Proglide™ devices (Abbott Vascular). Positive effects of these devices seem to consist of a lower infection rate, and shorter operation time and hospital stay. This conclusion was published in previous reports comparing techniques in patients in two different groups (cohort or randomized). Access techniques were never compared in one and the same patient; this research simplifies comparison because patient characteristics will be similar in both groups. METHODS/DESIGN: Percutaneous access of the CFA is compared to surgical cutdown in a single patient; in EVAR surgery, access is necessary in both groins in each patient. Randomization is performed on the introduction site of the larger main device of the endoprosthesis. The contralateral device of the endoprosthesis is smaller. When we use this type of randomization, both groups will contain a similar number of main and contralateral devices. Preoperative nose cultures and perineal cultures are obtained, to compare colonization with postoperative wound cultures (in case of a surgical site infection). Furthermore, patient comfort will be considered, using VAS-scores (Visual analog scale). Punch biopsies of the groin will be harvested to retrospectively compare skin of patients who suffered a surgical site infection (SSI) to patients who did not have an SSI. DISCUSSION: The PiERO trial is a multicenter randomized controlled clinical trial designed to show the consequences of using percutaneous access in EVAR surgery and focuses on the occurrence of surgical site infections. TRIAL REGISTRATION: NTR4257 10 November 2013, NL44578.042.13. |
format | Online Article Text |
id | pubmed-4570236 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-45702362015-09-16 A comparison of Percutaneous femoral access in Endovascular Repair versus Open femoral access (PiERO): study protocol for a randomized controlled trial Vierhout, Bastiaan P. Saleem, Ben R. Ott, Alewijn van Dijl, Jan Maarten de Kempenaer, Ties D. van Andringa Pierie, Maurice E. N. Bottema, Jan T. Zeebregts, Clark J. Trials Study Protocol BACKGROUND: Access for endovascular repair of abdominal aortic aneurysms (EVAR) is obtained through surgical cutdown or percutaneously. The only devices suitable for percutaneous closure of the 20 French arteriotomies of the common femoral artery (CFA) are the Prostar™ and Proglide™ devices (Abbott Vascular). Positive effects of these devices seem to consist of a lower infection rate, and shorter operation time and hospital stay. This conclusion was published in previous reports comparing techniques in patients in two different groups (cohort or randomized). Access techniques were never compared in one and the same patient; this research simplifies comparison because patient characteristics will be similar in both groups. METHODS/DESIGN: Percutaneous access of the CFA is compared to surgical cutdown in a single patient; in EVAR surgery, access is necessary in both groins in each patient. Randomization is performed on the introduction site of the larger main device of the endoprosthesis. The contralateral device of the endoprosthesis is smaller. When we use this type of randomization, both groups will contain a similar number of main and contralateral devices. Preoperative nose cultures and perineal cultures are obtained, to compare colonization with postoperative wound cultures (in case of a surgical site infection). Furthermore, patient comfort will be considered, using VAS-scores (Visual analog scale). Punch biopsies of the groin will be harvested to retrospectively compare skin of patients who suffered a surgical site infection (SSI) to patients who did not have an SSI. DISCUSSION: The PiERO trial is a multicenter randomized controlled clinical trial designed to show the consequences of using percutaneous access in EVAR surgery and focuses on the occurrence of surgical site infections. TRIAL REGISTRATION: NTR4257 10 November 2013, NL44578.042.13. BioMed Central 2015-09-14 /pmc/articles/PMC4570236/ /pubmed/26370286 http://dx.doi.org/10.1186/s13063-015-0911-y Text en © Vierhout et al. 2015 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Study Protocol Vierhout, Bastiaan P. Saleem, Ben R. Ott, Alewijn van Dijl, Jan Maarten de Kempenaer, Ties D. van Andringa Pierie, Maurice E. N. Bottema, Jan T. Zeebregts, Clark J. A comparison of Percutaneous femoral access in Endovascular Repair versus Open femoral access (PiERO): study protocol for a randomized controlled trial |
title | A comparison of Percutaneous femoral access in Endovascular Repair versus Open femoral access (PiERO): study protocol for a randomized controlled trial |
title_full | A comparison of Percutaneous femoral access in Endovascular Repair versus Open femoral access (PiERO): study protocol for a randomized controlled trial |
title_fullStr | A comparison of Percutaneous femoral access in Endovascular Repair versus Open femoral access (PiERO): study protocol for a randomized controlled trial |
title_full_unstemmed | A comparison of Percutaneous femoral access in Endovascular Repair versus Open femoral access (PiERO): study protocol for a randomized controlled trial |
title_short | A comparison of Percutaneous femoral access in Endovascular Repair versus Open femoral access (PiERO): study protocol for a randomized controlled trial |
title_sort | comparison of percutaneous femoral access in endovascular repair versus open femoral access (piero): study protocol for a randomized controlled trial |
topic | Study Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570236/ https://www.ncbi.nlm.nih.gov/pubmed/26370286 http://dx.doi.org/10.1186/s13063-015-0911-y |
work_keys_str_mv | AT vierhoutbastiaanp acomparisonofpercutaneousfemoralaccessinendovascularrepairversusopenfemoralaccesspierostudyprotocolforarandomizedcontrolledtrial AT saleembenr acomparisonofpercutaneousfemoralaccessinendovascularrepairversusopenfemoralaccesspierostudyprotocolforarandomizedcontrolledtrial AT ottalewijn acomparisonofpercutaneousfemoralaccessinendovascularrepairversusopenfemoralaccesspierostudyprotocolforarandomizedcontrolledtrial AT vandijljanmaarten acomparisonofpercutaneousfemoralaccessinendovascularrepairversusopenfemoralaccesspierostudyprotocolforarandomizedcontrolledtrial AT dekempenaertiesdvanandringa acomparisonofpercutaneousfemoralaccessinendovascularrepairversusopenfemoralaccesspierostudyprotocolforarandomizedcontrolledtrial AT pieriemauriceen acomparisonofpercutaneousfemoralaccessinendovascularrepairversusopenfemoralaccesspierostudyprotocolforarandomizedcontrolledtrial AT bottemajant acomparisonofpercutaneousfemoralaccessinendovascularrepairversusopenfemoralaccesspierostudyprotocolforarandomizedcontrolledtrial AT zeebregtsclarkj acomparisonofpercutaneousfemoralaccessinendovascularrepairversusopenfemoralaccesspierostudyprotocolforarandomizedcontrolledtrial AT vierhoutbastiaanp comparisonofpercutaneousfemoralaccessinendovascularrepairversusopenfemoralaccesspierostudyprotocolforarandomizedcontrolledtrial AT saleembenr comparisonofpercutaneousfemoralaccessinendovascularrepairversusopenfemoralaccesspierostudyprotocolforarandomizedcontrolledtrial AT ottalewijn comparisonofpercutaneousfemoralaccessinendovascularrepairversusopenfemoralaccesspierostudyprotocolforarandomizedcontrolledtrial AT vandijljanmaarten comparisonofpercutaneousfemoralaccessinendovascularrepairversusopenfemoralaccesspierostudyprotocolforarandomizedcontrolledtrial AT dekempenaertiesdvanandringa comparisonofpercutaneousfemoralaccessinendovascularrepairversusopenfemoralaccesspierostudyprotocolforarandomizedcontrolledtrial AT pieriemauriceen comparisonofpercutaneousfemoralaccessinendovascularrepairversusopenfemoralaccesspierostudyprotocolforarandomizedcontrolledtrial AT bottemajant comparisonofpercutaneousfemoralaccessinendovascularrepairversusopenfemoralaccesspierostudyprotocolforarandomizedcontrolledtrial AT zeebregtsclarkj comparisonofpercutaneousfemoralaccessinendovascularrepairversusopenfemoralaccesspierostudyprotocolforarandomizedcontrolledtrial |